Product Description: Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV[1][2].
Applications: COVID-19-anti-virus
Formula: C25H34N7O13PS
References: [1]Meleri Jones, et al. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 Sep;89(9):1620-1628./[2]Manasa Suresh, et al. Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. PLoS One. 2017 Jan 5;12(1):e0169631.
CAS Number: 942123-43-5
Molecular Weight: 703.62
Compound Purity: 99.87
Research Area: Infection
Solubility: DMSO : 80 mg/mL (ultrasonic)/H2O : 10 mg/mL (ultrasonic;warming;heat to 60°C)
Target: HBV;HCV
Deutsch
English
